Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488), a China-based pharmaceutical company, has entered into a licensing agreement with South Korean firm Kainos Medicine Inc., concerning Kainos’ ainuovirine (ACC007) and its fixed dose preparation ainuovirine, lamivudine, tenofovir disoproxil (ACC008). The agreement grants Aidea commercial, development, and promotion rights for these drugs globally, excluding the Chinese mainland, Hong Kong, Taiwan, and South Korea. In return, Aidea will pay Kainos royalties and profits based on varying ranges per region.
Building on an Existing Partnership
This licensing deal expands upon an existing relationship between the two companies. Initially, they formed a partnership in November 2020 and established a joint venture (JV) named Kaidea Global Pte in Singapore in April 2021. The JV’s focus is on the overseas promotion of ACC007, a novel non-nucleoside reverse transcriptase inhibitor with a unique structure. ACC007 was approved in China in June 2021 for the treatment of primary HIV-1 infection patients and was included in the National Reimbursement Drug List (NRDL) in December of the same year.
ACC008’s Market Progression
ACC008, another drug under the agreement, received approval in China in December of the previous year. This fixed dose combination therapy provides an additional option for the treatment of HIV-1 infection, further expanding the portfolio of available therapies in the global market.-Fineline Info & Tech
